CA
NZ
UK
AU
IND
US
Organigram has executed a strategic integration of Sanity Group into its global operations while appointing a series of new executives. This significant move enhances the company’s management infrastructure, aimed at ensuring an efficient alignment between both entities. Analysts suggest that the integration reflects Organigram's …
Market Sentiment Shifts with Healthcare Upgrade
This growth was attributed to strongDemandthrough its direct-to-consumer sales channel and increased contractManufacturingactivity. Despite this positive development, the company’s broader financial environment remains challenging, as it continues to face market pressures and elevated operational costs. The increase in revenue showcases the potential for continued …
A $500 monthly premium for health insurance under the Affordable Care Act (ACA) has ignited a debate about fairness in healthcare. Individuals, including those not currently employed, are finding themselves burdened by significant costs when obtaining coverage. This situation is especially pronounced for those …
The recent surge of a key drug stock has resulted in five-fold profits for investors, which reflects a broader trend of optimism in the healthcare sector. This rally underscores a strong market sentiment that is prompting traders to rethink their investment positions. The gains …
UroGen Pharma (NASDAQ:URGN) and IntraGel Therapeutics announced a strategic Option and Research License Agreement alongside a related equityInvestmentagreement. Under the investment agreement, UroGen will invest up to $7 million in IntraGel's equity securities, funding support for the Phase 2 clinical development of TumoCure, IntraGel's …
IceCure Medical (NASDAQ:ICCM) said the Institutional Review Board of West Cancer Center & Research Institute in Germantown, Tennessee, has granted approval for the company's post-marketing ChoICE Study evaluating ProSense cryoablation in the local treatment of low-risk breast cancer. The approval advances the study and …
• NBP shares fell approximately 7.58 percent to $1.83 shortly after market open, down from a prior close of $1.98.
Rein Therapeutics (NASDAQ:RNTX) said the FDA has granted Fast Track designation to LTI-03 for the treatment of idiopathic pulmonary fibrosis, or IPF. Fast Track designation is an FDA process intended to facilitate development and expedite review of drugs that treat serious conditions and address …
• The FDA grantedFast Track Designationto lead candidate LTI-03 for idiopathic pulmonary fibrosis.
Please wait processing your request...